Definity is owned by Lantheus Medcl.
Definity contains Perflutren.
Definity has a total of 8 drug patents out of which 0 drug patents have expired.
Definity was authorised for market use on 31 July, 2001.
Definity is available in injectable;intravenous dosage forms.
Definity can be used as method of using the drug substance/drug product for ultrasound imaging.
The generics of Definity are possible to be released after 04 May, 2037.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10022460 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(12 years from now) | |
US11395856 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10583207 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(12 years from now) | |
US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(14 years from now) | |
US11529431 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(14 years from now) | |
US11266750 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(14 years from now) | |
US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(14 years from now) | |
US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(14 years from now) |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic